List view / Grid view
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy…
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-300x278.jpg)
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-scaled-e1594985022657.jpg)
Late-stage trials in Sjögren’s disease and primary immune thrombocytopenia met…
Late-stage trials in Sjögren’s disease and primary immune thrombocytopenia met primary endpoints.
The merger deal between Novartis AG and Regulus Therapeutics is…
The merger deal between Novartis AG and Regulus Therapeutics is expected to push forward development of a potential first-in-class kidney disease drug.
The potentially multi-billion-dollar deal strengths Novartis’ late-stage pipeline for cardiovascular…
The potentially multi-billion-dollar deal strengths Novartis’ late-stage pipeline for cardiovascular therapies, signalling advancement of novel treatments for heart disease.
The PSMA-targeted radioligand is first to significantly improve radiographic progression-free…
The PSMA-targeted radioligand is first to significantly improve radiographic progression-free survival for PSMA–positive metastatic castration-resistant prostate cancer, shows study.
